Karyopharm Therapeutics Inc (FRA:25K)
€ 0.5734 -0.0194 (-3.27%) Market Cap: 84.88 Mil Enterprise Value: 143.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Karyopharm Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 02:00PM GMT
Release Date Price: €2.22 (+1.88%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I am happy to introduce our guests today, Richard Paulson, the President and CEO; and Reshma Rangwala, the CMO of Karyopharm Therapeutics. Thanks so much for joining us today.

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Thanks for having us, Maury.

Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

And we're going to do a fireside chat format. So maybe for those who are new to the story, if you can provide a 1-minute intro to Karyopharm.

Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director

Sure. I mean Karyopharm was founded in 2008 as an innovation and patient-focused company really driving a first-in-class focus on the selective inhibition of nuclear exports and developing an all-oral medicine, which inhibits XPO1. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot